Visual Abstract Summary: SURMOUNT-3 Phase 3 Trial Objective: To evaluate the efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in achieving additional weight loss in adults with overweight or obesity who … Read More
GLP-1 agonist
GZGI Trial: Orforglipron in Obesity
GZGI TRIAL Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Phase 2, randomized, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of orforglipron, an oral non-peptide GLP-1 receptor agonist, for weight reduction in adults with obesity, or … Read More